1. A PHASE I TRIAL OF 19‐28Z CAR‐T CELLS POST‐HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION (HDT‐ASCT) FOR RELAPSED AND REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL). (June 2017) Authors: Sauter, C.; Riviere, I.; Senechal, B.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Moskowitz, C.; Giralt, S.; Matasar, M.; Curran, K.; Park, J.; Sadelain, M.; Brentjens, R. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 138 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PHASE I CLINICAL TRIAL OF CD19‐TARGETED 19‐28Z/4‐1BBL "ARMORED" CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION. (12th June 2019) Authors: Batlevi, C.L.; Palomba, M.L.; Park, J.; Mead, E.; Santomasso, B.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R.; Yang, J.; Kane, P.; Hall, M.; Bernal, Y.; Lund, N.; Diamonte, C.; Pineda, J.; Halton, E.; Moskowitz, C.; Younes, A.; Sadelain, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 166 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗